CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, announced today new preclinical data from its novel G9a program for sickle cell disease (SCD). The data were reported during an oral presentation at the 59 Annual Meeting & Exposition of the American Society of Hematology (ASH) in Atlanta, Ga. In addition, the company announced that its drug development candidate, EZM8266, a G9a inhibitor, will begin IND-enabling studies in 2018. It is widely understood within the SCD research community that elevation of fetal hemoglobin, which is normally silenced after birth, has disease-modifying potential for...
|
